Cross-sectional study on prevalences of psychiatric disorders in mutation carriers of Huntington's disease compared with mutation-negative first-degree relatives

Journal of Clinical Psychiatry

Volumn 69, Issue 11, 2008, Pages 1804-1810

  Van Duijn, Erik ^a,b   Kingma, Elisabeth M ^a   Timman, Reinier ^a   Zitman, Frans G ^a   Tibben, Aad ^a   Roos, Raymund A C ^a   Van Der Mast, Rose C ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Rivierduinen   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BRAIN DEGENERATION; COMORBIDITY; CONTROLLED STUDY; FEMALE; GENE MUTATION; HETEROZYGOTE; HUMAN; HUNTINGTON CHOREA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MANIA; MINI MENTAL STATE EXAMINATION; NETHERLANDS; OBSESSIVE COMPULSIVE DISORDER; PREVALENCE; PRIORITY JOURNAL; RELATIVE;

EID: 57349084008     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v69n1116     Document Type: Article

References (38)

1. Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993;72(6):971-983
2. Walker FO. Huntington's disease. Lancet 2007;369:218-228
3. Anderson KE, Marder KS. An overview of psychiatric symptoms in Huntington's disease. Curr Psychiatry Rep 2001;3:379-388
4. Kirkwood SC, Su JL, Conneally PM, et al. Progression of symptoms in the early and middle stages of Huntington's disease. Arch Neurol 2001;58:273-278
5. Marshall J, White K, Weaver M, et al. Specific psychiatric manifestations among preclinical Huntington disease mutation carriers. Arch Neurol 2007;64:116-121
6. Hamilton JM, Salmon DP, Corey-Bloom J, et al. Behavioural abnormalities contribute to functional decline in Huntington's disease. J Neurol Neurosurg Psychiatry 2003;74:120-122
7. Nehl C, Paulsen JS, and The Huntington Study Group. Cognitive and psychiatric aspects of Huntington disease contribute to functional capacity. J Nerv Ment Dis 2004;192(1):72-74
8. Di Maio L, Squitieri F, Napolitano G, et al. Suicide risk in Huntington's disease. J Med Genet 1993;30:293-295
9. Paulsen JS, Hoth KF, Nehl C, et al. Critical periods of suicide risk in Huntington's disease. Am J Psychiatry 2005;162:725-731
10. van Duijn E, Kingma EM, van der Mast RC. Psychopathology in verified Huntington's disease gene carriers. J Neuropsychiatry Clin Neurosci 2007;19:441-448
11. van der Meer LB, Timman R, Trijsburg W, et al. Attachment in families with Huntington's disease. Patient Educ Couns 2006;63(1-2):246-254
12. Vamos M, Hambridge J, Edwards M, et al. The impact of Huntington's disease on family life. Psychosomatics 2007;48:400-404
13. Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord 1996;11:136-142
14. Shoulson I, Fahn S. Huntington disease: clinical care and evaluation. Neurology 1979;29:1-3
15. The American College of Medical Genetics/American Society of Human Genetics Huntington Disease Genetic Testing Working Group. Laboratory guidelines for Huntington disease genetic testing. Am J Hum Genet 1998;62:1243-1247
16. World Health Organization. Composite International Diagnostic Interview [computer program]. Translation: ter Smitten MH, Smeets RMW, van den Brink W. Geneva, Switzerland: World Health Organization; 1997
17. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 2000
18. Andrews G, Peters L. The psychometric properties of the Composite International Diagnostic Interview. Soc Psychiatry Psychiatr Epidemiol 1998;33(2):80-88
19. Folstein M, Folstein S, McHugh P. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198
20. Bijl RV, Ravelli A, van Zessen G. Prevalence of psychiatric disorder in the general population: results of the Netherlands Mental Health Survey and Incidence Study (NEMESIS). Soc Psychiatry Psychiatr Epidemiol 1998;33(12):587-595
21. Gifi A. Nonlinear Multivariate Analysis. Chicester, UK: Wiley; 1990
22. SPSS Inc. Statistical Package for the Social Sciences for Windows, release 12.0.1. Chicago, Ill: SPSS; 2003
23. Julien CL, Thompson JC, Wild S, et al. Psychiatric disorders in preclinical Huntington's disease. J Neurol Neurosurg Psychiatry 2007;78:939-943
24. Paulsen JS, Nehl C, Hoth KF, et al. Depression and stages of Huntington's disease. J Neuropsychiatry Clin Neurosci 2005;17:496-502
25. De Marchi N, Morris M, Menella R, et al. Association of obsessive-compulsive disorders and pathological gambling with Huntington's disease in an Italian pedigree: possible association with Huntington's disease mutation. Acta Psychiatr Scand 1998;97:62-65
26. Scicutella A. Late-life obsessive-compulsive disorder and Huntington's disease [letter]. J Neuropsychiatry Clin Neurosci 2000;12:288-289
27. Patzold T, Brüne M. Obsessive-compulsive disorder in Huntington disease: a case of isolated obsessions successfully treated with sertraline. Neuropsychiatry Neuropsychol Behav Neurol 2002;15(3):216-219
28. Cummings JL, Cunningham K. Obsessive-compulsive disorder in Huntington's disease. Biol Psychiatry 1992;31:263-270
29. Murgod UA, Saleem Q, Anand A, et al. A clinical study of patients with genetically confirmed Huntington's disease from India. J Neurol Sci 2001;190:73-78
30. Craufurd D, Thompson JC, Snowden JS. Behavioural changes in Huntington disease. Neuropsychiatry Neuropsychol Behav Neurol 2001;14(4):219-226
31. Anderson KE, Louis ED, Stern Y, et al. Cognitive correlates of obsessive and compulsive symptoms in Huntington's disease. Am J Psychiatry 2001;158:799-801
32. Beglinger LJ, Langbehn DR, Duff K, et al. Probability of obsessive and compulsive symptoms in Huntington's disease. Biol Psychiatry 2007;61:415-418
33. Steele JW, Faulds D, Sorkin EM. Tiapride: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in geriatric agitation. Drugs Aging 1993;3(5):460-478
34. Allain H, Dautzenberg PHJ, Maurer K, et al. Double blind study of tiapride versus haloperidol and placebo in agitation and aggressiveness in elderly patients with cognitive impairment. Psychopharmacology 2000;148:361-366
35. Mayberg HS, Starkstein SE, Peyser CE, et al. Paralimbic frontal lobe hypometabolism in depression associated with Huntington's disease. Neurology 1992;42:1791-1797
36. Freire Maia AS, Reis Barbosa E, Rossi Menezes P, et al. Relationship between obsessive-compulsive disorders and diseases affecting primarily the basal ganglia. Rev Hosp Clín Fac Med S Paulo 1999;54:213-221
37. Witjes-Ané MN, Vegter-van der Vlis M, van Vugt JP, et al. Cognitive and motor functioning in gene carriers for Huntington's disease: a baseline study. J Neuropsychiatry Clin Neurosci 2003;15:7-16
38. Timman R, Roos RAC, Maat-Kievit A, et al. Adverse effects of predictive testing for Huntington disease underestimated: long-term effects 7-10 years after the test. Health Psychol 2004;23:189-197